Incannex Healthcare

CompanyAustralia

Incannex Healthcare develops one asset, in phase 2 (IHL-42X in obstructive sleep apnea). Mostly small molecule acting on CNR1, CA1 and CNR2; based in Australia.

1
Asset
Furthest stage: Phase 2; 2
Trials: 1
Signal

Pipeline

1

IHL-42X
Combines dronabinol cannabinoid receptor agonism with acetazolamide carbonic anhydrase inhibition to reduce sleep-disordered breathing.
Phase 2, Small molecule, CNR1, CA1, obstructive sleep apnea

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms4
Trials2
Signals2
Similar companies6